Dr. Lal Path Labs Ltd. has informed the Exchange that Board of Directors at its meeting held on April 30, 2026, recommended Final Dividend of Rs. 4 per equity share.
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts less than Nifty Smallcap 250 and 2.0 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Lal PathLabs reported FY2026 revenue of Rs. 27,629 million, up 12.2% from Rs. 24,614 million in FY2025. Profit after tax grew 3.6% to Rs. 5,098 million from Rs. 4,922 million. The Board recommended a final dividend of Rs. 4 per share (40% on face value), taking total dividend for the year to Rs. 20.5 per share. Key corporate actions include acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited and incorporation of a wholly owned subsidiary in Dubai. The auditors issued an unmodified (clean) opinion on both standalone and consolidated results. Exceptional item of Rs. 301 million was recorded for impact of new Labour Codes. EPS stood at Rs. 30.24 for FY2026 versus Rs. 29.20 (restated) in FY2025.
Positive signals for shareholders: strong cash generation of Rs. 6,357 million from operations, clean audit, and generous total dividend of Rs. 20.5 per share. Expansion through acquisition and international subsidiary signals growth focus.